Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients

Hamid Sayar, Jeffrey T. Bunning, Therese J. Bocklage, Sang Joon Lee, Edward Libby, Ian Rabinowitz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Venous thromboembolism (VTE) occurs at an increased incidence in cancer patients. A cancer-related hypercoagulable state has been considered to play role in this phenomenon. Preclinical data suggest an association between tumor expression of MET proto-oncogene (MET) and a hypercoagulable state, resulting in VTE. We investigated this association in this retrospective study. Thirty-five cancer patients with documented VTE and no relevant predisposing factors were compared with 35 matched cancer patients without VTE who served as controls. Pathology specimens of all patients and controls were stained by immunohistochemistry (IHC) for MET protein. Intensity of reactivity to the MET antibody was read as 0 (negative), 1+ (equivocal), and 2+ (positive). The pathologists were blinded to the patient VTE status. The MET reactivity in tissue sections were compared between the two cohorts. No significant difference was observed between the two groups for MET expression. This study's findings indicate no association between the reactivity for MET protein as measured through an immunohistochemical technique, and the incidence of VTE in cancer patients.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalOncology Research
Volume19
Issue number2
DOIs
StatePublished - 2010

Fingerprint

Venous Thromboembolism
Neoplasms
Proto-Oncogenes
Incidence
Causality
Proteins
Retrospective Studies
Immunohistochemistry
Pathology
Antibodies

Keywords

  • Hepatocyte growth factor
  • MET
  • Thromboembolism
  • Thrombosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sayar, H., Bunning, J. T., Bocklage, T. J., Lee, S. J., Libby, E., & Rabinowitz, I. (2010). Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients. Oncology Research, 19(2), 93-97. https://doi.org/10.3727/096504010X12828372551786

Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients. / Sayar, Hamid; Bunning, Jeffrey T.; Bocklage, Therese J.; Lee, Sang Joon; Libby, Edward; Rabinowitz, Ian.

In: Oncology Research, Vol. 19, No. 2, 2010, p. 93-97.

Research output: Contribution to journalArticle

Sayar, H, Bunning, JT, Bocklage, TJ, Lee, SJ, Libby, E & Rabinowitz, I 2010, 'Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients', Oncology Research, vol. 19, no. 2, pp. 93-97. https://doi.org/10.3727/096504010X12828372551786
Sayar, Hamid ; Bunning, Jeffrey T. ; Bocklage, Therese J. ; Lee, Sang Joon ; Libby, Edward ; Rabinowitz, Ian. / Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients. In: Oncology Research. 2010 ; Vol. 19, No. 2. pp. 93-97.
@article{9379684ac6af48a0bec8cd4078577442,
title = "Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients",
abstract = "Venous thromboembolism (VTE) occurs at an increased incidence in cancer patients. A cancer-related hypercoagulable state has been considered to play role in this phenomenon. Preclinical data suggest an association between tumor expression of MET proto-oncogene (MET) and a hypercoagulable state, resulting in VTE. We investigated this association in this retrospective study. Thirty-five cancer patients with documented VTE and no relevant predisposing factors were compared with 35 matched cancer patients without VTE who served as controls. Pathology specimens of all patients and controls were stained by immunohistochemistry (IHC) for MET protein. Intensity of reactivity to the MET antibody was read as 0 (negative), 1+ (equivocal), and 2+ (positive). The pathologists were blinded to the patient VTE status. The MET reactivity in tissue sections were compared between the two cohorts. No significant difference was observed between the two groups for MET expression. This study's findings indicate no association between the reactivity for MET protein as measured through an immunohistochemical technique, and the incidence of VTE in cancer patients.",
keywords = "Hepatocyte growth factor, MET, Thromboembolism, Thrombosis",
author = "Hamid Sayar and Bunning, {Jeffrey T.} and Bocklage, {Therese J.} and Lee, {Sang Joon} and Edward Libby and Ian Rabinowitz",
year = "2010",
doi = "10.3727/096504010X12828372551786",
language = "English",
volume = "19",
pages = "93--97",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "2",

}

TY - JOUR

T1 - Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients

AU - Sayar, Hamid

AU - Bunning, Jeffrey T.

AU - Bocklage, Therese J.

AU - Lee, Sang Joon

AU - Libby, Edward

AU - Rabinowitz, Ian

PY - 2010

Y1 - 2010

N2 - Venous thromboembolism (VTE) occurs at an increased incidence in cancer patients. A cancer-related hypercoagulable state has been considered to play role in this phenomenon. Preclinical data suggest an association between tumor expression of MET proto-oncogene (MET) and a hypercoagulable state, resulting in VTE. We investigated this association in this retrospective study. Thirty-five cancer patients with documented VTE and no relevant predisposing factors were compared with 35 matched cancer patients without VTE who served as controls. Pathology specimens of all patients and controls were stained by immunohistochemistry (IHC) for MET protein. Intensity of reactivity to the MET antibody was read as 0 (negative), 1+ (equivocal), and 2+ (positive). The pathologists were blinded to the patient VTE status. The MET reactivity in tissue sections were compared between the two cohorts. No significant difference was observed between the two groups for MET expression. This study's findings indicate no association between the reactivity for MET protein as measured through an immunohistochemical technique, and the incidence of VTE in cancer patients.

AB - Venous thromboembolism (VTE) occurs at an increased incidence in cancer patients. A cancer-related hypercoagulable state has been considered to play role in this phenomenon. Preclinical data suggest an association between tumor expression of MET proto-oncogene (MET) and a hypercoagulable state, resulting in VTE. We investigated this association in this retrospective study. Thirty-five cancer patients with documented VTE and no relevant predisposing factors were compared with 35 matched cancer patients without VTE who served as controls. Pathology specimens of all patients and controls were stained by immunohistochemistry (IHC) for MET protein. Intensity of reactivity to the MET antibody was read as 0 (negative), 1+ (equivocal), and 2+ (positive). The pathologists were blinded to the patient VTE status. The MET reactivity in tissue sections were compared between the two cohorts. No significant difference was observed between the two groups for MET expression. This study's findings indicate no association between the reactivity for MET protein as measured through an immunohistochemical technique, and the incidence of VTE in cancer patients.

KW - Hepatocyte growth factor

KW - MET

KW - Thromboembolism

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=79951519418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951519418&partnerID=8YFLogxK

U2 - 10.3727/096504010X12828372551786

DO - 10.3727/096504010X12828372551786

M3 - Article

VL - 19

SP - 93

EP - 97

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 2

ER -